Mast cells (MCs) are tissue resident immune cells that participate in a variety of allergic and other inflammatory conditions. In most tissues, MCs are found in close proximity to nerve endings of primary afferent neurons that signal pain (i.e. nociceptors). Activation of MCs causes the release of a plethora of mediators that can activate these nociceptors and promote pain. Although MCs are ubiquitous, conditions associated with systemic MC activation give rise primarily to two major types of pain, headache and visceral pain. In this study we therefore examined the extent to which systemic MC degranulation induced by intraperitoneal administration of the MC secretagogue compound 48/80 activates pain pathways that originate in different parts of the body and studied whether this action can lead to development of behavioral pain hypersensitivity. Using c-fos expression as a marker of central nervous system neural activation, we found that intraperitoneal administration of 48/80 leads to the activation of dorsal horn neurons at two specific levels of the spinal cord; one responsible for processing cranial pain, at the medullary/C2 level, and one that processes pelvic visceral pain, at the caudal lumbar/rostral sacral level (L6-S2). Using behavioral sensory testing, we found that this nociceptive activation is associated with development of widespread tactile pain hypersensitivity within and outside the body regions corresponding to the activated spinal levels. Our data provide a neural basis for understanding the primacy of headache and visceral pain in conditions that involve systemic MC degranulation. Our data further suggest that MC activation may lead to widespread tactile pain hypersensitivity.
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Introduction
Mast cells (MCs) are immune cells that play an important role in allergy and anaphylactic response. In recent years, clinical and preclinical evidence has accumulated to support a cardinal role for MCs in a host of other inflammatory and functional painful disorders including inflammatory/irritable bowl disease (Klooker et al., 2010; Wood, 2011) , bladder pain syndrome/interstitial cystitis (Theoharides et al., 1995) and migraine headache (Levy, 2009). MCs respond to immunological (e.g. IgE) and non-immunological stimuli (e.g. physical stimuli, neuropeptides, chemokines, stress hormones). Upon their activation by these stimuli, MCs secrete a plethora of proinflammatory algogenic mediators, primarily through the process of degranulation (Rao and Brown, 2008) . These secreted factors in turn can activate chemo-sensitive primary afferent nociceptive neurons with receptive fields that terminate in the vicinity of the activated MCs (Ahluwalia et al., 1998; Barbara et al., 2007; Greene et al., 1988; Levy et al., 2007) . Theoretically, release of algogenic mediators from activated MCs should promote pain from any tissue where MCs are localized near the peripheral terminals of chemosensitive nociceptive afferents. Nonetheless, in conditions associated with systemic MC degranulation, such as MC activation syndrome and systemic mastocytosis, visceral pain and headache are the prominent pains (Ashina and Ashina, 2005; Hamilton et al., 2011; Horan and Austen, 1991) . While other types of pain have been reported, particularly in mastocytosis (Hermine et al., 2008 ) the higher prevalence of headache and visceral pain related to MC diseases remains poorly understood and may be, at least in part, due to relatively increased neuroimmune interactions between MCs and afferents innervating visceral organs (as the source of visceral pain) and the meninges (as the source of the headache).
Upon inflammation, persistent activation of nociceptors that innervate visceral organs as well as the meninges can lead to long-term changes in the responsiveness of the second-order dorsal horn neurons upon which they terminate, a phenomenon termed central sensitization. Because these central nociceptive neurons also receive convergent input from cutaneous afferents, this central sensitization can be manifested as pain hypersensitivity in tissues or body regions that are somatotopically distinct from those becoming inflamed. For example, persistent activation of
